Biotech company Biogen (NASDAQ:BIIB) reported Q1 CY2025 results exceeding the market’s revenue expectations , with sales up 6.1% year on year to $2.43 billion. Its non-GAAP profit of $3.02 per ...

Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow before the bell. Here’s what you need to know. Biogen beat analysts’ revenue expectations by 1.8% last quarter ...

Biogen Inc. (BIIB), currently valued at $18 billion by market capitalization, reported stronger-than-expected earnings for the first quarter of 2025, with earnings per share (EPS) of $3.02 ...

Biotech company Biogen (NASDAQ:BIIB) reported Q1 CY2025 results exceeding the market’s revenue expectations , with sales up 6.1% year on year to $2.43 billion. Its non-GAAP profit of $3.02 per share ...

Biogen Q1 EPS hit $3.02 vs. $2.52 estimate; revenue rose 6% to $2.43 billion, beating the $2.23 billion consensus. Rare disease sales rose 33% to $563 million; Spinraza revenue climbed to $423.9 ...

Beloved husband, dad, papa and friend, Nellis Burkhart passed away on April 27, 2025, leaving his family and loved ones heartbroken as he made his final walk down the “River of No Return.” ...

EVANSVILLE — An opportunity of this caliber is why Bo Burkhart chose to move back to Southwestern Indiana. The Bosse graduate is slated to become the next boys basketball coach at Washington ...

Julie Burkhart has been fighting for decades to provide abortions in some of the most rural and conservative areas of the U.S. After Wyoming banned abortion in 2022, she joined other advocates to ...

Biogen Inc. (BIIB) came out with quarterly earnings of $3.02 per share, missing the Zacks Consensus Estimate of $3.26 per share. This compares to earnings of $3.67 per share a year ago. These ...

Biogen isn’t shy about aspirations to expand beyond neurology and further establish itself in immunology and rare diseases. Recent business development deals have focused on enhancing the ...

TOKYO -- Japanese drugmaker Eisai is overhauling its U.S. operations as the company seeks ways to overcome the hurdles to wide adoption of its flagship Alzheimer's disease treatment. The company ...